PHAXIAM Therapeutics
Carole Sansoz (Bucher) is currently the Head of pharmaceutical and CMC regulatory affairs at ERYTECH Pharma. Prior to this role, Carole worked as a Scientific Officer at the conseil de l'Europe. She holds a Master of Science in Pharmacy Administration and Pharmacy Policy and Regulatory Affairs from Purdue University, as well as a Doctor of Pharmacy from Université de Strasbourg.
PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.